{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:37:06Z","timestamp":1793975826672,"version":"4.8.0"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA286450"],"award-info":[{"award-number":["R37CA286450"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA22183"],"award-info":[{"award-number":["R50CA22183"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA097186"],"award-info":[{"award-number":["P50CA097186"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA266452"],"award-info":[{"award-number":["R01CA266452"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA274336"],"award-info":[{"award-number":["R50CA274336"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA277368"],"award-info":[{"award-number":["R21CA277368"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA221836"],"award-info":[{"award-number":["R50CA221836"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35CA274442"],"award-info":[{"award-number":["R35CA274442"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-20-1-0111"],"award-info":[{"award-number":["W81XWH-20-1-0111"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0229"],"award-info":[{"award-number":["W81XWH-21-1-0229"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0278"],"award-info":[{"award-number":["W81XWH-22-1-0278"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-1-0689"],"award-info":[{"award-number":["W81XWH-18-1-0689"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0264"],"award-info":[{"award-number":["W81XWH-21-1-0264"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT94252410755"],"award-info":[{"award-number":["HT94252410755"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-2-0043"],"award-info":[{"award-number":["W81XWH-17-2-0043"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["PC-SYNERGY"],"award-info":[{"award-number":["PC-SYNERGY"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017453","name":"Institute for Prostate Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2021184"],"award-info":[{"award-number":["2021184"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA276308"],"award-info":[{"award-number":["R01CA276308"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA230617"],"award-info":[{"award-number":["R37CA230617"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00334566"],"award-info":[{"award-number":["RS-2024-00334566"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort (n = 52 patients, 1\u201319 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression (P = 0.2). In urothelial carcinoma (n = 20, 2\u20136 tumors per patient), HER2 expression was more frequent, with \u22652+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent in urothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0069","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:01:32Z","timestamp":1754485292000},"page":"1419-1428","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-6060","authenticated-orcid":false,"given":"Hyun Jung","family":"Lee","sequence":"first","affiliation":[{"name":"1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington."},{"name":"2Department of Pathology, Pusan National University School of Medicine, Yangsan, Korea."},{"name":"3Pusan National University Yangsan Hospital, Yangsan, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-6567","authenticated-orcid":false,"given":"Roman","family":"Gulati","sequence":"additional","affiliation":[{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-5683","authenticated-orcid":false,"given":"Erolcan","family":"Sayar","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4889-6818","authenticated-orcid":false,"given":"Radhika A.","family":"Patel","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7069-9047","authenticated-orcid":false,"given":"Pushpa","family":"Itagi","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4328-488X","authenticated-orcid":false,"given":"Helen M.","family":"Richards","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3209-592X","authenticated-orcid":false,"given":"Thomas","family":"Persse","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-3024","authenticated-orcid":false,"given":"Sonali","family":"Arora","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1483-7202","authenticated-orcid":false,"given":"Ilsa","family":"Coleman","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1787-644X","authenticated-orcid":false,"given":"Mohamed","family":"Adil","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4051-5802","authenticated-orcid":false,"given":"Samantha L.","family":"Schuster","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3752-5335","authenticated-orcid":false,"given":"Farinaz","family":"Shokri","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8447-8209","authenticated-orcid":false,"given":"Jonathan L.","family":"Wright","sequence":"additional","affiliation":[{"name":"6Department of Urology, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-8044","authenticated-orcid":false,"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8621-9569","authenticated-orcid":false,"given":"Lawrence D.","family":"True","sequence":"additional","affiliation":[{"name":"1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0509","authenticated-orcid":false,"given":"Meagan","family":"Chambers","sequence":"additional","affiliation":[{"name":"8Department of Pathology, Stanford University, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1720-5654","authenticated-orcid":false,"given":"Jessica E.","family":"Hawley","sequence":"additional","affiliation":[{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1365-0702","authenticated-orcid":false,"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5510-0661","authenticated-orcid":false,"given":"Michael T.","family":"Schweizer","sequence":"additional","affiliation":[{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-5726","authenticated-orcid":false,"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-0295","authenticated-orcid":false,"given":"R. Bruce","family":"Montgomery","sequence":"additional","affiliation":[{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0897-1050","authenticated-orcid":false,"given":"Andrew C.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2350-4575","authenticated-orcid":false,"given":"Funda","family":"Vakar-Lopez","sequence":"additional","affiliation":[{"name":"1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington."},{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-5333","authenticated-orcid":false,"given":"Colm","family":"Morrissey","sequence":"additional","affiliation":[{"name":"6Department of Urology, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8921-6091","authenticated-orcid":false,"given":"Hung-Ming","family":"Lam","sequence":"additional","affiliation":[{"name":"6Department of Urology, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-7272","authenticated-orcid":false,"given":"Gavin","family":"Ha","sequence":"additional","affiliation":[{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0819-9638","authenticated-orcid":false,"given":"Maria S.","family":"Tretiakova","sequence":"additional","affiliation":[{"name":"1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0809-6425","authenticated-orcid":false,"given":"Michael C.","family":"Haffner","sequence":"additional","affiliation":[{"name":"1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington."},{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-4954","authenticated-orcid":false,"given":"Ruben","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"7Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"2025082502382513300_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V","article-title":"Specificity within the EGF family\/ErbB receptor family signaling network","volume":"20","author":"Riese","year":"1998","journal-title":"Bioessays"},{"key":"2025082502382513300_bib2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025082502382513300_bib3","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"2025082502382513300_bib4","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"2025082502382513300_bib5","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"2025082502382513300_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.semdp.2015.02.011","article-title":"Predictive markers in breast cancer: an update on ER and HER2 testing and reporting","volume":"32","author":"Calhoun","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"2025082502382513300_bib7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"2025082502382513300_bib8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2025082502382513300_bib9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"2025082502382513300_bib10","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody\u2013drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025082502382513300_bib11","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1080\/00498254.2020.1755909","article-title":"Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice","volume":"50","author":"Okamoto","year":"2020","journal-title":"Xenobiotica"},{"key":"2025082502382513300_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025082502382513300_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2025082502382513300_bib14","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/j.annonc.2023.09.1840","article-title":"654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study","volume":"34","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"key":"2025082502382513300_bib15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-09-2546","article-title":"Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer","volume":"16","author":"Minner","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025082502382513300_bib16","first-page":"2643","article-title":"Her-2\/neu (p185 neu) protein expression in the natural or treated history of prostate cancer","volume":"7","author":"Osman","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2025082502382513300_bib17","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0022-5347(05)64462-X","article-title":"Her2 expression in prostatic cancer: a comparison with mammary carcinoma","volume":"168","author":"Jorda","year":"2002","journal-title":"J Urol"},{"key":"2025082502382513300_bib18","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"Her-2-neu expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2025082502382513300_bib19","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","article-title":"HER3 is an actionable target in advanced prostate cancer","volume":"81","author":"Gil","year":"2021","journal-title":"Cancer Res"},{"key":"2025082502382513300_bib20","doi-asserted-by":"crossref","first-page":"1011885","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front Oncol"},{"key":"2025082502382513300_bib21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cam4.432","article-title":"HER2 as a target in invasive urothelial carcinoma","volume":"4","author":"Bellmunt","year":"2015","journal-title":"Cancer Med"},{"key":"2025082502382513300_bib22","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/pros.23171","article-title":"Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer","volume":"76","author":"Roudier","year":"2016","journal-title":"Prostate"},{"key":"2025082502382513300_bib23","doi-asserted-by":"crossref","first-page":"e128728","DOI":"10.1172\/jci.insight.128728","article-title":"Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy","volume":"4","author":"Winters","year":"2019","journal-title":"JCI insight"},{"key":"2025082502382513300_bib24","doi-asserted-by":"crossref","first-page":"e162907","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"2025082502382513300_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcp\/aqw206","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"146","author":"Bartley","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"2025082502382513300_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"2025082502382513300_bib27","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Invest"},{"key":"2025082502382513300_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41698-024-00599-6","article-title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates","volume":"8","author":"Ajkunic","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2025082502382513300_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.clgc.2023.05.014","article-title":"Metastatic bladder cancer expression and subcellular localization of Nectin-4 and Trop-2 in variant histology: a rapid autopsy study","volume":"21","author":"Ghali","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2025082502382513300_bib30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"key":"2025082502382513300_bib31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"2025082502382513300_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2025082502382513300_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1101\/gr.221028.117","article-title":"SvABA: genome-wide detection of structural variants and indels by local assembly","volume":"28","author":"Wala","year":"2018","journal-title":"Genome Res"},{"key":"2025082502382513300_bib34","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2025082502382513300_bib35","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1101\/gr.180281.114","article-title":"TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data","volume":"24","author":"Ha","year":"2014","journal-title":"Genome Res"},{"key":"2025082502382513300_bib36","doi-asserted-by":"crossref","first-page":"e1003118","DOI":"10.1371\/journal.pcbi.1003118","article-title":"Software for computing and annotating genomic ranges","volume":"9","author":"Lawrence","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"2025082502382513300_bib37","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2025082502382513300_bib38","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.7326\/ANNALS-24-01409","article-title":"Response of human epidermal growth factor receptor 2\u2013expressing prostate cancer to trastuzumab deruxtecan","volume":"177","author":"Lap","year":"2024","journal-title":"Ann Intern Med"},{"key":"2025082502382513300_bib39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/6495","article-title":"A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2\/neu tyrosine kinase","volume":"5","author":"Craft","year":"1999","journal-title":"Nat Med"},{"key":"2025082502382513300_bib40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2003.08.010","article-title":"HER2 and COX2 expression in human prostate cancer","volume":"40","author":"Edwards","year":"2004","journal-title":"Eur J Cancer"},{"key":"2025082502382513300_bib41","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.juro.2010.04.077","article-title":"Her-2\/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis","volume":"184","author":"Neto","year":"2010","journal-title":"J Urol"},{"key":"2025082502382513300_bib42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/0008-5472.CAN-16-1656","article-title":"HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone","volume":"77","author":"Day","year":"2017","journal-title":"Cancer Res"},{"issue":"Suppl 4","key":"2025082502382513300_bib43","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.2024.42.4_suppl.538","article-title":"HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: associations and clinical outcomes for advanced bladder cancer","volume":"42","author":"Aggen","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025082502382513300_bib44","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"key":"2025082502382513300_bib45","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.urology.2003.10.040","article-title":"HER-2\/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder","volume":"63","author":"Coogan","year":"2004","journal-title":"Urology"},{"key":"2025082502382513300_bib46","doi-asserted-by":"crossref","first-page":"e2400879","DOI":"10.1200\/PO-24-00879","article-title":"Testing and interpretation of human epidermal growth factor receptor 2 protein expression and ERBB2 gene amplification in advanced urothelial carcinoma","volume":"9","author":"Koshkin","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2025082502382513300_bib47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/modpathol.2013.135","article-title":"Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy","volume":"27","author":"Ross","year":"2014","journal-title":"Mod Pathol"},{"issue":"Suppl 7","key":"2025082502382513300_bib48","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/1538-7445.AM2023-472","article-title":"Abstract 472: HER2 as a therapeutic target in bladder cancer","volume":"83","author":"Tang","year":"2023","journal-title":"Cancer Res"},{"key":"2025082502382513300_bib49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11523-024-01056-x","article-title":"Frequency and nature of genomic alterations in ERBB2-altered urothelial bladder cancer","volume":"19","author":"Leary","year":"2024","journal-title":"Target Oncol"},{"issue":"Suppl 5","key":"2025082502382513300_bib50","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1200\/JCO.2025.43.5_suppl.828","article-title":"Molecular subtypes, NECTIN4\/HER2 expression, and clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) or muscle invasive bladder cancer (MIBC): exploratory analyses from JAVELIN Bladder 100 and the Tempus database","volume":"43","author":"Eckstein","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025082502382513300_bib51","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and metastases: implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod Pathol"},{"key":"2025082502382513300_bib52","first-page":"2440","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2025082502382513300_bib53","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/s12885-016-2703-5","article-title":"Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques","volume":"16","author":"Nedjadi","year":"2016","journal-title":"BMC cancer"},{"key":"2025082502382513300_bib54","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.3390\/cancers15245721","article-title":"The genomic landscape of urothelial carcinoma with high and low ERBB2 expression","volume":"15","author":"Hadadi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025082502382513300_bib55","first-page":"4935","article-title":"Critical overview of HER2 assessement in bladder cancer: what is missing for a better therapeutic approach?","volume":"37","author":"Cimpean","year":"2017","journal-title":"Anticancer Res"},{"key":"2025082502382513300_bib56","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0069\/3639092\/crc-25-0069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/8\/1419\/3644928\/crc-25-0069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/8\/1419\/3644928\/crc-25-0069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T06:38:44Z","timestamp":1756103924000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/8\/1419\/764321\/Patterns-of-HER2-Expression-in-Metastatic-Prostate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0069","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29978438","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29978423","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29978429","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29978417","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29978435","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29978426","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29978432","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29978420","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7998446","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}